SCHEMBL6205709

SCHEMBL6205709

O=C1CCc2cc(-c3cccnc3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 14/20 1.00
CYP11B2 P19099 14/20 1.00
CYP1A2 P05177 7/20 1.00
CYP2C9 P11712 2/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C19 P33261 1/20 0.62
TBXAS1 P24557 1/20 0.59
PDE3B Q13370 1/20 0.59
PDE3A Q14432 1/20 0.59
TDP2 O95551 2/20 0.58
CYP19A1 P11511 3/20 0.57
CYP17A1 P05093 1/20 0.57
GRM1 Q13255 1/20 0.56
HSD17B1 P14061 2/20 0.55
SRD5A1 P18405 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7505292 0.91 CYP11B1 (0.83) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL24135424 0.81 CYP11B2 (0.68) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL28655414 0.81 HSD17B1 (0.78) CYP11B1CYP11B2CYP1A2GRM1HSD17B1
SCHEMBL29892591 0.81 PARP10 (0.71) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL1745161 0.80 HSD17B1 (0.71) CYP11B1CYP11B2CYP1A2TDP2HSD17B1
SCHEMBL27125699 0.79 CYP11B1 (0.65) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL31060388 0.79 CYP11B1 (0.64) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL5414626 0.77 CYP1A2 (0.61) CYP11B1CYP11B2CYP1A2CYP19A1GRM1
SCHEMBL6206369 0.77 CYP11B1 (0.62) CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4
SCHEMBL2433975 0.76 CYP1A2 (0.60) CYP11B1CYP11B2CYP1A2GRM1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098891-B1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA GMBH (DE) 2005-08-10 EP disclosed
EP-1157015-B1 USE OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LIPOMETABOLIC DISORDERS, OBESITAS AND TYP II DIABETES AVENTIS PHARMA GMBH (DE) 2005-05-11 EP disclosed
EP-1173176-B1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA GMBH (DE) 2004-05-26 EP disclosed
US-6476059-B1 Use of polycyclic 2-aminothiazole systems for the treatment of obesity AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-11-05 US disclosed
EP-1173176-A1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY Aventis Pharma Deutschland GmbH (DE) 2002-01-23 EP disclosed
EP-1157015-A1 POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2001-11-28 EP disclosed
US-6251922-B1 TREATMENT OF OBESITY AND DIABETES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-06-26 US disclosed
EP-1098891-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-05-16 EP disclosed
US-6159996-A Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 US disclosed
WO-2000051602-A1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000051995-A1 POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000004006-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed